Biora Therapeutics, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
Davidson Kempner Capital Management and its affiliates have disclosed a 9.90% beneficial ownership stake in Biora Therapeutics, Inc., primarily through convertible notes, subject to a 9.90% ownership blocker.
Margaret Ellen Taggett has disclosed a 6.6% passive ownership stake in Biora Therapeutics, Inc., holding 297,000 shares of common stock.
Context Capital Management, along with its affiliates, has reported a beneficial ownership of 0.5% in BIORA THERAPEUTICS, INC., totaling 22,025 shares of common stock.